DARA BioSciences, Inc.

DARA BioSciences Announces Launch of Bionect for Treatment of Skin Irritation and Burns Associated With Radiation Therapy for Cancer

RALEIGH, N.C., June 6, 2012 (GLOBE NEWSWIRE) -- DARA BioSciences, Inc. (Nasdaq:DARA) (the "Company" or "DARA"), an emerging oncology and oncology-support specialty pharmaceutical company, announced the commercial launch of Bionect

DARA BioSciences, Inc.

DARA BioSciences Announces New Organizational Responsibilities in Preparation for the Launch of New Products and to Strengthen Product Development Capabilities

RALEIGH, N.C., May 29, 2012 (GLOBE NEWSWIRE) -- DARA BioSciences, Inc. (Nasdaq:DARA) (the "Company" or "DARA"), an emerging oncology and oncology-support specialty pharmaceutical company, today announced several key changes in its organizational structure. These changes afford DARA the opportunity to better position the company for growth as it prepares for the launch of two new products. This growth is primarily attributable to the acquisition by DARA of the privately held Oncogenerix, Inc., earlier this year. The realignment of responsibilities will help ensure proper organizational structure as well as the staffing of a sales and marketing department to execute the successful launch of both products. 

DARA BioSciences, Inc.

DARA BioSciences Reports Financial Results for the First Quarter 2012 and Provides Key Highlights of the Company's Business Milestones

RALEIGH, N.C., May 21, 2012 (GLOBE NEWSWIRE) -- DARA BioSciences, Inc. (Nasdaq:DARA) (the "Company" or "DARA") today announced the financial results for the period ending March 31, 2012. The Company also detailed the quarter's key corporate activities, including an overview of the commercial portfolio, which includes two FDA-registered products for the oncology and oncology supportive care markets.

DARA BioSciences, Inc.

DARA BioSciences Announces New Analysis of Patient Self-Reported Diary Results in a Phase 2a Clinical Trial of KRN5500 in Patients With Cancer and Neuropathic Pain

External Data Analysis Confirms Earlier Published Drug Efficacy Signal in Patients With Treatment-Refractory Neuropathic Pain

DARA BioSciences, Inc.

DARA BioSciences Closes $10.25 Million Public Offering and Regains Compliance With NASDAQ's Stockholders' Equity Requirement

RALEIGH, N.C., May 1, 2012 (GLOBE NEWSWIRE) -- DARA BioSciences, Inc. (Nasdaq:DARA) (the "Company" or "DARA") announced that at a closing completed on April 26, 2012, it received $10,250,000 in gross proceeds from the sale of Series B-2 convertible preferred stock (convertible into a total of 10,250,000 shares of common stock) and warrants to purchase an equal number of shares of common stock.

DARA BioSciences, Inc.

DARA BioSciences to Raise $10.1 Million in Public Offering

RALEIGH, N.C., April 9, 2012 (GLOBE NEWSWIRE) -- DARA BioSciences, Inc. (Nasdaq:DARA) (the "Company" or "DARA") announced that it entered into definitive securities purchase agreements with certain investors in connection with a public offering providing for the sale of $10,100,000 of shares of Series B-2 convertible preferred stock (which are convertible into a total of 10,100,000 shares of common stock), five year warrants to purchase up to 5,050,000 shares of common stock at an exercise price of $1.00 per share and five year warrants to purchase up to 5,050,000 shares of common stock at an exercise price of $1.25 per share. The Series B-2 convertible preferred stock is convertible at any time into shares of common stock at an initial conversion price of $1.00 per share The conversion price represents approximately a 25% discount to the volume weighted average trading price of the Company's common stock during the five trading days preceding entry into the securities purchase agreements.

DARA BioSciences, Inc.

DARA BioSciences Obtains U.S. Rights to Co-Promote Bionect(R), an FDA Approved Topical Hyaluronic Acid, Exclusively in the Radiation and Oncology Markets

RALEIGH, N.C., March 26, 2012 (GLOBE NEWSWIRE) -- DARA BioSciences, Inc. (Nasdaq:DARA) announced today that it entered into an exclusive agreement with Innocutis Holdings, LLC ("Innocutis") for U.S. commercial rights to Bionect

DARA BioSciences, Inc.

DARA BioSciences Signs Exclusive Agreement With Uman Pharma for U.S. Commercialization Rights to Gemcitabine

RALEIGH, N.C., Feb. 15, 2012 (GLOBE NEWSWIRE) -- DARA BioSciences, Inc. (Nasdaq:DARA) announced today that it entered into an exclusive U.S. agreement with Uman Pharma Inc. for commercial rights to gemcitabine, DARA's second newly licensed anticancer agent. In 2010, gemcitabine generated branded (GEMZAR®-Eli Lilly) sales of $780 million, according to IMS data. It went off patent in 2011 in the U.S., and a year earlier in Europe. The drug is widely prescribed as first-line therapy for ovarian, breast, lung, and pancreatic cancers.

DARA BioSciences, Inc.

DARA BioSciences Signs Definitive Agreement to Raise $1.7 Million in Registered Direct Offering

RALEIGH, N.C., Jan. 18, 2012 (GLOBE NEWSWIRE) -- DARA BioSciences, Inc. (Nasdaq:DARA) today announced that it has entered into a definitive agreement with one institutional investor providing for the sale of $1.7 million of shares of Series B convertible preferred stock (which are convertible into a total of 1,238,616 shares of common stock) and warrants to purchase 619,308 shares of common stock. Subject to certain ownership limitations, the Series B preferred stock is convertible at any time at the option of the holder into shares of common stock at a conversion price of $1.3725 per share. The transaction is expected to close on or about January 20, 2012, subject to satisfaction of customary closing conditions.

DARA BioSciences, Inc.

DARA BioSciences Announces Acquisition of U.S. Marketing Rights to Soltamox(TM), an FDA Approved Liquid Formulation of Tamoxifen for the Treatment of Breast Cancer